 Home > Biochemistry News > Biotechnology News > Reduce the mortality of specific hospitalized patients by 20%, the phase 3 clinical results of the new crown neutralizing antibody combination are positive

Reduce the mortality of specific hospitalized patients by 20%, the phase 3 clinical results of the new crown neutralizing antibody combination are positive

 Last Update: 2021-09-07
 Source: Internet
 Author: User

Tags

17 4 20b

2 4 toxicity

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 16, 2021, Regeneron announced that its research neutralizing antibody therapy REGEN-COV (casirivimab and imdevimab) has obtained positive preliminary results in the Phase 3 clinical trial RECOVERY

REGEN-COV is a cocktail therapy consisting of two monoclonal antibodies, which can be administered by intravenous infusion or subcutaneous injection

A total of 9785 COVID-19 hospitalized patients were enrolled in this phase 3 clinical trial, with an average age of 62 years.

The results of the test showed that, similar to previous studies, the mortality rate of seronegative patients on day 28 was twice that of serologically positive patients (30% vs.

In addition, among seronegative patients, the median hospital stay in the experimental group was 4 days shorter (13 days vs.

Note: The original text has been deleted

Reference materials:

[1] REGEN-COV™ (CASIRIVIMAB AND IMDEVIMAB) PHASE 3 RECOVERY TRIAL MEETS PRIMARY OUTCOME, IMPROVING SURVIVAL IN HOSPITALIZED COVID-19 PATIENTS LACKING AN IMMUNE RESPONSE TO SARS-COV-2.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.